



## **MedX Health to Present at the SNN Network Canada Virtual Event December 7 – 9, 2021**

**MISSISSAUGA, ONTARIO / December 6, 2021 /** MedX Health Corp. (TSXV: MDX) (“MedX” or the “Company”), a global leader in teledermatology, is pleased to announce its participation in the SNN Network Canada Virtual Event, taking place virtually December 7<sup>th</sup> – 9<sup>th</sup>, 2021.

MedX President Dermatological Services, Mike Druhan, will present the Company’s vision for scaling global access to its unique dermatological image capture technology and fully integrated telemedicine platform, DermSecure®. The screening platform features high-resolution image capture technology that enables the accurate evaluation of moles, lesions and other skin conditions, providing a complete, virtual dermatological assessment by a certified dermatologist within just 72 hours.

The conference will be a live, interactive online event where investors are invited to ask the Company questions in real-time. An archived webcast will be made available for attendees who cannot join the event live.

### **SNN Network Canada Virtual Event 2021**

MedX Corporate Presentation

Date & Time: Thursday, December 9 at 12:00 PM ET

Webcast Registration Link: <https://www.webcaster4.com/Webcast/Page/2813/43866>

To book a one-on-one investor meeting with MedX or to watch the Company presentation, please register for the virtual event here:

<https://canada.snn.network/signup>

One-on-one meetings will be scheduled and conducted via private, secure video conference through the conference event platform.

For those unable to attend the live presentation, all company presentation webcasts will be available directly on the conference event platform on this link under the tab “Agenda”:  
[www.canada.snn.network/agenda](http://www.canada.snn.network/agenda)

### **About MedX Health Corp.**

MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also imbedded in its products SIAMETRICS®, SIMSYS®, and MoleMate®, which MedX

manufactures in its ISO 13485 certified facility. SIAMETRICS®, SIMSYS®, and MoleMate® include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the US, Australia, New Zealand, the European Union, Brazil and Turkey. Visit <https://medxhealth.com>.

*Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.*

**Contact:**

**Bill Mitoulas, Investor Relations**

**MedX Health Corp.**

[bill@medxhealth.com](mailto:bill@medxhealth.com)

+1-416-479-9547